2 results
Approved WMORecruiting
To evaluate, in patients with end stage knee osteoarthritis, the in vivo disease (tissue structure) modifying activity of celecoxib, as a selective COX-2 inhibitor, in addition to its inflammation regulatory properties, compared to naproxen as a…
Approved WMOCompleted
To evaluate the effects on ovarian function with the NOMAC/E2 COC in a group of women aged 18-35 years.